Bitter taste receptors (TAS2Rs) on the tongue probably evolved to evoke signals for avoiding ingestion of plant toxins. We found expression of TAS2Rs on human airway smooth muscle (ASM) and considered these to be avoidance receptors for inhalants that, when activated, lead to ASM contraction and bronchospasm. TAS2R agonists such as saccharin, chloroquine and denatonium evoked increased intracellular calcium ([Ca 2+ ] i ) in ASM in a G-, phospholipase C (PLC)-and inositol trisphosphate (IP 3 ) receptor-dependent manner, which would be expected to evoke contraction. Paradoxically, bitter tastants caused relaxation of isolated ASM and dilation of airways that was threefold greater than that elicited by -adrenergic receptor agonists. The relaxation induced by TAS2Rs is associated with a localized [Ca 2+ ] i response at the cell membrane, which opens large-conductance Ca 2+ -activated K + (BK Ca ) channels, leading to ASM membrane hyperpolarization. Inhaled bitter tastants decreased airway obstruction in a mouse model of asthma. Given the need for efficacious bronchodilators for treating obstructive lung diseases, this pathway can be exploited for therapy with the thousands of known synthetic and naturally occurring bitter tastants.
a r t i c l e s
Asthma and chronic obstructive pulmonary disease (COPD) together affect 300 million individuals worldwide. The major source of morbidity and mortality from both diseases is airway obstruction, which in part is due to actively constricted smooth muscle of the bronchi 1 . Although airway resistance in COPD has variable degrees of reversibility, owing to structural changes that result from smoking, therapies for COPD and asthma include antagonists directed at bronchoconstrictive receptors and agonists directed at receptors that relax ASM 2, 3 . The major receptor signaling family in ASM that regulates contraction and relaxation are G protein-coupled receptors (GPCRs) 3 . There is an ongoing effort to identify GPCR pathways leading to regulation of airway tone, thereby providing new treatment strategies for asthma and COPD. This is particularly relevant because the incidence of both diseases is increasing, and at least one-half of all patients have inadequate control of the disease with currently available agents 4, 5 .
Unexpectedly, we recently found expression of several bitter taste receptors in isolated human ASM as part of a pan-GPCR screening effort 6 . The cognate G protein for bitter taste receptors, gustducin, is also expressed in human ASM 7, 8 . Receptors for bitter tastes on the tongue are thought to have evolved for avoidance of plant-based toxins 9, 10 . These GPCRs consist of at least 25 receptor subtypes, each recognizing a repertoire of agonists that usually overlaps with other bitter taste receptors, creating a redundant, broadly tuned avoidance and rejection network 9, [11] [12] [13] . The finding of bitter taste receptors on ASM led to our original hypothesis that certain bronchospastic disorders, such as occupational asthma 14 , might be caused by environmental inhalants acting at these airway receptors, leading to contraction and bronchoconstriction. This notion was based on the fact that bitter taste receptors couple to increases in [Ca 2+ ] i in specialized taste cells of the tongue, and this signal is also found with known bronchoconstrictive GPCRs such as those for histamine, acetylcholine and bradykinin in ASM cells 2 . By various approaches, we found that bitter tastants also increase [Ca 2+ ] i in ASM cells but unexpectedly found that bitter taste receptor agonists are bronchodilators with greater efficacy than any known therapeutic agent. These receptors transduce the relaxation response in ASM by a novel mechanism involving receptor-generated Gβγ activation of PLC and a partitioned [Ca 2+ ] i transient that opens cell surface K + channels, resulting in membrane hyperpolarization.
RESULTS

Human ASM expresses bitter taste receptors coupled to [Ca 2+ ] i
In initial studies, we found that several known bitter taste receptor agonists (such as saccharin, chloroquine and denatonium) evoked increased [Ca 2+ ] i in cultured human ASM cells (Fig. 1a-c) . We found the [Ca 2+ ] i responses in ASM cells to these bitter tastants to be similar in magnitude to those for known G q -coupled bronchoconstrictive GPCR agonists such as histamine and bradykinin (Fig. 1c) . These results prompted quantitative RT-PCR studies with primers for 25 TAS2R genes. Of note, the numerical designations of the TAS2R genes have recently changed, and here we use this new nomenclature (see a r t i c l e s 1 3 0 0 VOLUME 16 | NUMBER 11 | NOVEMBER 2010 nature medicine http://www.genenames.org). We found multiple TAS2R transcripts to be expressed in human ASM, with the TAS2R10, TAS2R14 and TAS2R31 subtypes being the most highly expressed ( Table 1) . Further screens with additional bitter tastants revealed [Ca 2+ ] i responses in ASM to aristocholic acid, strychnine, quinine, colchicine and yohimbine (Fig. 1c) . We found a relatively low response in ASM to colchicine, which activates TAS2R4 (expressed at intermediate levels in ASM, as determined by RT-PCR) and no response to salicin, which exclusively activates TAS2R16 (ref. 10) but was not detected in ASM by RT-PCR. The robust response to strychnine (which activates TAS2R10 and TAS2R46) is also consistent with TAS2R10 being highly expressed in ASM. Thus, in ASM, the [Ca 2+ ] i response to bitter tastants is concordant with a rank order based on agonist specificity and the bitter taste receptor subtype expression in these cells. Immunofluorescence microscopy of human ASM cells with polyclonal antisera directed against four receptors found by RT-PCR to be expressed at the mRNA level (TAS2R10, TAS2R14, TAS2R31 and TAS2R19) and three receptors whose mRNAs were not detected (TAS2R7, TAS2R38 and TAS2R43) revealed cell surface expression of the former four receptors but not of the latter three (Supplementary Fig. 1 ). These studies also revealed expression of the α subunit of gustducin in these cells (Supplementary Fig. 1 ). We found no [Ca 2+ ] i response to the sweet receptor agonists sucralose and SC45647, and the response to saccharin (which also activates sweet taste receptors) was not blocked by the sweet receptor antagonist lactisole (Supplementary Fig. 2 ).
Transfection of ASM cells with siRNA directed against TAS2R10 decreased TAS2R10 mRNA levels by 36 ± 1.8% compared to the scrambled siRNA control. Under these conditions of TAS2R10 knockdown, the [Ca 2+ ] i response induced by the TAS2R10 agonist strychnine was decreased by 26 ± 2.0% as compared with the scrambled siRNA control (P < 0.05 versus control). In additional studies, we incubated ASM cells with medium alone or polyclonal antisera directed against TAS2R10, TAS2R7 or isotype-specific IgG and then determined the strychnine-induced [Ca 2+ ] i . TAS2R10 antisera decreased strychnineinduced [Ca 2+ ] i responses in a dose-dependent manner (maximal inhibition of ~77%, Supplementary Fig. 3) , consistent with the RT-PCR and immunofluorescence results showing expression of this bitter taste receptor. In contrast, antisera against TAS2R7 (which is not expressed in ASM) at the same titers had no significant effect on [Ca 2+ ] i stimulation, nor did isotype-specific IgG (Supplementary Fig. 3 ). Taken together, these studies confirm expression of bitter taste receptors on ASM cells and link expression to bitter tastantmediated [Ca 2+ ] i signaling. The increase in [Ca 2+ ] i in human ASM cells elicited by bitter tastants was not dependent on the presence of extracellular Ca 2+ , the response was ablated by the Gβγ inhibitor gallein and the PLCβ inhibitor U73122, and it was partially inhibited by the IP 3 receptor antagonist 2APB (Fig. 1d) . These results in Bitter taste receptors evoke airway relaxation We initially assumed that bitter taste receptors evoked ASM contraction, as the increase in [Ca 2+ ] i promoted by some of the bitter tastants in human ASM was similar in magnitude to other ligands acting on bronchoconstrictive GPCRs. However, in isolated intact mouse airways, chloroquine, denatonium and quinine caused dosedependent relaxation, with a maximal response of >90% loss of the active contraction evoked by acetylcholine or serotonin (Fig. 2a,b) . The maximal relaxation response to the β-adrenergic receptor agonist isoproterenol under the same experimental conditions was a 30 ± 9.2% reduction in active tension (Fig. 2a) . We also found that bitter tastants relax baseline tracheal ring tension ( Supplementary Fig. 4 ).
The relaxation response to bitter tastants was fully reversible, as washing tracheal rings while maintaining the presence of the contractile agent alone resulted in a return to contraction that was equivalent in magnitude to the control condition ( Supplementary Fig. 5 ). Bitter tastants also relax human ASM. In fourth-order bronchi obtained from nondiseased portions of human lung tissues, chloroquine or saccharin induced a 50−80% reduction in active tension in acetylcholinecontracted rings (Supplementary Fig. 6 ). Bitter tastant-mediated airway relaxation was not altered by the cyclooxygenase inhibitor indomethacin or the nitric oxide synthase inhibitor l-NAME (data not shown), suggesting a direct activation of ASM receptors rather than a secondary response resulting from the release of bronchoactive ligands from airway epithelial cells. Airway relaxation observed with β-agonists is due to β 2 -adrenergic receptor coupling to adenylyl cyclase, leading to an increase in cAMP and subsequent PKA activation 2 . However, we found no evidence for chloroquine-induced increases in cAMP or PKA activation in intact cultured ASM cells, as assessed by a sensitive radioimmunoassay or a r t i c l e s by the PKA-mediated phosphorylation of vasodilator-stimulated phosphoprotein (VASP), respectively (Fig. 2c) . In a set of serial dosing and washout experiments with intact airways and a submaximal dose of chloroquine, we found that exposure to both chloroquine and isoproterenol resulted in relaxation that was greater than that found with either compound alone (Fig. 2d) . These data indicate that bitter tastants evoke marked airway relaxation that is reversible, is not due to cell injury (because ASM functional contraction and relaxation are not impaired after washout), is not cAMP dependent and is additive with β-adrenergic agonists.
ASM bitter receptors signal to localized [Ca 2+ ] i and BK Ca To further ascertain the mechanism by which bitter taste receptors evoke ASM relaxation, we used magnetic twisting cytometry 15 to measure dynamic changes in stiffness of isolated human ASM cells (Fig. 3) . In these experiments, magnetic particles attached to the cell by a peptide linker provide a highly quantitative measurement of single-cell stiffness, with isoproterenol and histamine exposure resulting in the expected relaxation and contraction from baseline, respectively (Fig. 3a) . Chloroquine and saccharin exposure (Fig. 3a) resulted in ASM relaxation at the single-cell level, confirming that these bitter tastants act directly on smooth muscle cells. The relaxation response to saccharin was not blocked by the PKA inhibitor H89 (Fig. 3b) , confirming results from cAMP and VASP phosphorylation measurements. Inhibition of PLC by U73122 eliminated the saccharin-induced relaxation of isolated ASM (Fig. 3b) . Fig. 7 ) and also inhibited chloroquinemediated relaxation of intact airway rings (Supplementary Fig. 8 ).
One potential mechanism for Ca 2+ -mediated relaxation in ASM is hyperpolarization due to stimulation of BK ca channels. These channels are known to be expressed on human ASM 16 (which we confirmed; Supplementary Fig. 1 ) and have been reported to regulate airway tone 17 . To test whether the observed relaxation is due to bitter tastant-triggered Ca 2+ activation of BK Ca , we pretreated human ASM cells with medium alone, the Ca 2+ -dependent K + channel antagonist charybdotoxin or the specific BK Ca channel antagonist iberiotoxin. Pretreatment with both antagonists ablated saccharin-mediated ASM relaxation, as assessed in isolated cells (Fig. 3b) . Similar results were found with chloroquine (data not shown). Pretreatment with iberiotoxin also attenuated chloroquine-induced relaxation of isolated mouse tracheal rings (Fig. 3c) . Relaxation of ASM following BK Ca activation would be expected to be from hyperpolarization of the cell membrane 18 . We loaded ASM cells with a membrane potential-sensitive fluorescent dye 19 , and incubation with KCl and histamine resulted in the anticipated procontractile membrane depolarization (Fig. 3d) . Incubation with the bitter tastants chloroquine and saccharin resulted in membrane hyperpolarization (Fig. 3d) , which is inhibited by iberiotoxin (Fig. 3e) 20 . To define the characteristics of saccharin-induced [Ca 2+ ] i increases in ASM cells as compared to those from histamine, we performed high-resolution real-time confocal imaging in Fluo-3-loaded cells. Localized [Ca 2+ ] i signals were detected at the slender ends and sarcolemmal regions of ASM upon exposure to saccharin (Fig. 4a) . This response was rapid (observed within 2.5 s in the crosssectional studies, Fig. 4a,b) , and the magnitude was greater than at the central region of the myocytes (Fig. 4a) . In contrast, the response to histamine in ASM cells caused a relatively delayed rise in [Ca 2+ ] i throughout the cell (Fig. 4c,d) , without the localized features observed with saccharin. When using the line-scan mode at regions within 1 μm and parallel to the cell membrane of ASM cells, we detected spatially and temporally discernible [Ca 2+ ] i events very early after the application of saccharin, before the subsequent sustained localized rise in [Ca 2+ ] i (Fig. 4e) . These results confirm the notion that saccharin promotes localized [Ca 2+ ] i signals in ASM cells.
Bitter tastants counteract asthmatic bronchoconstriction Collectively, the above results all pointed to a previously unknown ASM relaxation pathway that might be used for treating reversible obstructive lung diseases such as asthma. To assess this potential, we administered bitter tastants by inhalation in the context of a mouse model of allergic airway inflammation and bronchial hyper-responsiveness. We sensitized mice to ovalbumin and then repetitively challenged them with inhaled ovalbumin, which resulted in acute airway inflammation (Fig. 5a,b) . We measured airway resistance in these intact, sedated, intubated mice at baseline, after inhalation of the bronchoconstrictor methacholine, and then after inhalation of bitter tastants during the bronchoconstrictive phase. The positive control for these studies was inhaled albuterol, a β-agonist that is the most commonly used bronchodilator for treating asthma. In the ovalbumin-sensitized mice, the concentration of inhaled methacholine required to increase baseline airway resistance by four-to fivefold was 8 mg ml −1 , compared to ≥16 mg ml −1 for nonsensitized mice, confirming the airway hyperreactivity phenotype. Inhaled aerosolized quinine (150 μg) decreased airway resistance in normal and sensitized mice by 53 ± 3% and 50 ± 8%, respectively (Fig. 5c,d) . Bronchodilatory effects were also found with denatonium (200 μg), which decreased airway resistance by 44 ± 6% in the normal mice and 57 ± 4% in the sensitized mice. Albuterol (3 μg) showed less reduction of airway resistance compared to quinine in the ovalbumin-challenged mice (Fig. 5d) , suggesting that bitter tastants may be more effective than β-agonists in an inflammatory hyper-responsive state such as asthma.
DISCUSSION
GPCRs expressed on ASM represent the major family of signaling receptors that regulate airway tone and diameter. In asthma, multiple locally generated ligands act on these receptors leading to bronchoconstriction. The GPCRs mediating bronchoconstriction couple to G αq , increase [Ca 2+ ] i and trigger ASM contraction. In contrast, GPCRs coupled to G αs increase cAMP, relax ASM and bronchodilate, with the β 2 -adrenergic receptor being the target for β-agonists, the most commonly used therapeutic for bronchospasm. Identification of new ASM receptors that lead to bronchoconstriction and dilation further refines our understanding of the signaling network at play in asthma, leading to potential new therapeutic approaches. Here we found that several GPCRs belonging to the bitter taste receptor family are expressed on human ASM. A recent report 21 also identified bitter taste receptors on motile cilia of airway epithelial cells that increase beat frequency, which may represent a mechanical defense against noxious inhalants. These receptors are also found in the anterior nasal cavity, where they promote sneezing and regulate respiratory rate 22 . Binding to bitter taste receptors increases [Ca 2+ ] i in ASM via a Gβγ-, PLCβ-and IP 3 receptor-dependent manner. Although increased [Ca 2+ ] i would be expected to cause ASM constriction, such as that observed with G αq -coupled receptor activation, we observed marked relaxation in intact airways of mice and humans, and in isolated human ASM cells.
The dose-response curves for [Ca 2+ ] i stimulation and ASM relaxation by a given bitter tastant showed equivalent EC 50 values, suggesting a connection between this intracellular signal and the physiological response. Indeed, depletion of sarcoplasmic reticulum Ca 2+ resulted in the loss of bitter tastant-mediated increases in [Ca 2+ ] I and the relaxation effect in intact airway rings. Spatially restricted increases in [Ca 2+ ] i were observed in response to bitter tastants, which promoted BK Ca -channel opening and membrane hyperpolarization. The basis for the restricted [Ca 2+ ] i response from bitter tastants remains to be defined. Notably, we observed a small degree of depolarization from bitter tastants in the context of BK Ca blockade, suggesting that the two calcium pools (histamine receptor-induced versus TAS2R-induced) may have some overlap. Nevertheless, the net effect of the histaminemediated [Ca 2+ ] i increase is depolarization and contraction, whereas for bitter tastants it is hyperpolarization and relaxation.
Lastly, aerosolized administration of bitter tastants relaxed the airways in a mouse model of allergic inflammation, indicating that . The studies were carried out with a dose of methacholine that resulted in a four-to five-fold increase in airway resistance over baseline (≥16 mg ml −1 in control mice and 8 mg ml −1 in ovalbumin-challenged mice). *P < 0.01 versus methacholine; #P < 0.05 versus methacholine. Data are presented as means ± s.e.m. a r t i c l e s the pathway has therapeutic relevance in a diseased state. The evolutionary basis for bronchodilating bitter taste receptors on ASM remains speculative. They may act in a compensatory manner to acyl-homoserine lactones, which are agonists of these receptors 23 and are secreted by Gram-negative bacteria 24 during bronchitis or pneumonia. This action may provide protection against bronchospasm or airway closure, which might otherwise lead to worsening disease.
There is an unmet need for additional therapeutic options in the treatment of obstructive airway diseases such as asthma. Here we show that agents that bind bitter taste receptors cause marked bronchodilation of intact airways greater than that promoted by β-agonists. Furthermore, the effect of bitter taste receptors seems to be additive with that of β-agonists, which is consistent with their different mechanisms of action and suggests further studies on combination therapy could be considered. The choice of compounds that could be developed for this purpose is extensive given the marked structural diversity between bitter tastants. Indeed, there are many known synthetic agents, developed for other purposes, that activate bitter taste receptors 10 and are nontoxic. Furthermore, there are thousands of plant-derived bitter tastants and their metabolites that could have favorable therapeutic profiles 10 .
METHODS
Methods and any associated references are available in the online version of the paper at http://www.nature.com/naturemedicine/. 
Note: Supplementary information is available on the Nature Medicine website.
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[Ca 2+ ] i , cAMP and membrane potential measurements. Primary human ASM cells were obtained from a commercial source (Clonetics) and maintained as previously described 25 , with experiments done in cells at passages 3−8. To detect changes in [Ca 2+ ] i , we loaded attached cells (80,000 cells per well) with Fluo-4 AM (BD Biosciences) and probenecid for 1 h; agonists were added by an automated pipetting system in triplicate, and the 525 nm signals were generated by excitation at 485 nm with a Flex Station II (Molecular Devices). The doses were as follows: 0, 10, 18, 32, 56, 100, 178, 320, 560 and 1,000 μM saccharin; 0, 10, 18, 32, 56, 100, 178 and 320 μM chloroquine. Unless otherwise stated, the medium for these experiments contained 1.5 mM calcium. In some studies, ASM cells were transfected with 4 μg TAS2R10-targeting siRNA (Invitrogen) or 4 μg of a scrambled-sequence siRNA control by electroporation (Nucleofector, Lonza). cAMP was measured by a 125 I-cAMP based radioimmunoassay 26 . The effects of bitter tastants on membrane potential of whole ASM cells was measured with a membrane potential-sensitive fluorescent dye (Molecular Devices) as previously described 19 in a 96-well plate format.
Ex vivo intact airway physiology. All mouse studies were approved by the Animal Care and Use Committee, and human tissue studies were approved by the Institutional Review Board of the University of Maryland-Baltimore. We excised 5-mm sections of trachea from FVB/N mice (Taconic) and studied them in an isometric myograph system (Radnoti) as previously described 27 . A passive tension of 5 mN was applied for each ring for a baseline. For relaxation studies, rings were contracted with acetylcholine (1.0 mM) or serotonin (1.0 mM), which were maintained during addition of multiple doses of isoproterenol or bitter tastants. For studies where acetylcholine was used to contract the rings, the doses were as follows: 0, 0.01, 0.03, 0.10, 0.30, 1.0 and 3.0 μM isoproterenol; 0, 25, 50, 75, 100, 125, 250, 300, 375, 500 and 1,000 μM chloroquine; 0, 10, 30, 60, 100, 200, 300, 1,000 and 2,000 μM quinine; and 0, 10, 30, 100, 300, 1,000 and 3,000 μM denatonium. For studies where serotonin was used to contract the rings, the doses were as follows: 0, 1, 3, 7.5, 10, 25, 50, 75, 100, 250, 500 and 750 μM chloroquine; and 0, 30, 60, 100, 200, 300 and 1,000 μM quinine. Fourth-order bronchi from human lungs were obtained from extracted tissue specimens at the time of therapeutic or diagnostic surgical procedures. Bronchi were dissected from regions without gross pathology, and the rings were prepared and studied in a similar manner to those of the mice.
Magnetic twisting cytometry.
Dynamic changes in baseline cell stiffness were measured as an indicator of contraction and relaxation of isolated human ASM cells by magnetic twisting cytometry as described previously 15 . For each individual ASM cell, baseline stiffness was measured for the first 60 s, then, after addition of the drug, stiffness was measured continuously for the next 540 s. In some experiments, cells were pre-exposed to vehicle or inhibitors for 10 min before addition of GPCR agonists. Bitter taste receptor expression. Total RNA was extracted from human ASM cells, and reverse transcription was carried out with 2 μg RNA and oligo-dT primers (Invitrogen). Real-time PCR was carried out with an Applied Biosystems 7300 Real Time PCR system with methods previously described in detail 31 . Specific primers for the 25 TAS2R genes, TAS1R1, TAS1R2, ADRB2, ADORA1, LTB4R and GAPDH were obtained from Applied Biosystems. Data were analyzed with the ΔΔC t method, with ADRB2 as the reference 32 . The PCR products derived from primers for TAS2R10, TAS2R14, TAS2R31, TAS2R5, TAS2R4 and TAS2R19 were sequenced and verified to be from the respective human bitter taste receptor. Immunofluorescence microscopy was carried out on fixed cells as described 25 .
Confocal imaging of regional and local [Ca
Ovalbumin sensitization and pulmonary function testing. Sensitization of 6-week-old BALB/c mice (Taconic) was carried out by intraperitoneal injections of 100 μg ovalbumin (Sigma) in 200 μl alum, or alum alone (control) on days 0 and 14. Mice were then challenged with 1.0% aerosolized ovalbumin on days 19, 21 and 24. Twenty-four hours after the last challenge, mice were sedated and intubated, then ventilated, and measurements of airway resistance were taken as previously described 33 . Mice were challenged with sequential doses of 2.0, 4.0, 8.0, 16, 32 and 64 mg ml −1 of methacholine (Methapharm) in the nebulizer until a dose resulted in a sustained airway resistance of approximately four-to fivefold greater than baseline. Three minutes after the last methacholine inhalation, the bitter tastants quinine (150 μg) or denatonium (200 μg, both from Sigma), or the β-agonist albuterol (3.0 μg; Letco Medical) were administered by aerosol over 10 s. Resistance measurements (Raw, cm H 2 O ml −1 s −1 ) were taken every 30 s throughout the experiment.
Statistical analyses. Dose-response curves for [Ca 2+ ] i and ex vivo tracheal ring studies were analyzed by iterative nonlinear (sigmoidal) least-squares fitting.
Results from all studies were compared with paired or unpaired two-way t tests (depending on study design), with P < 0.05 considered significant. When multiple comparisons were sought, analysis of variance with post hoc t tests was used with a correction for multiple comparisons. Data are presented as means ± s.e.m.
